Longeveron (NASDAQ:LGVN) Trading 2.5% Higher – What’s Next?

Longeveron Inc. (NASDAQ:LGVN) traded up 2.5% during trading on Tuesday . The stock traded as high as $0.7831 and last traded at $0.7727. 119,736 shares were traded during trading, a decline of 70% from the average session volume of 394,153 shares. The stock had previously closed at $0.7540.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. HC Wainwright decreased their target price on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Maxim Group downgraded Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings downgraded Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 5th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Longeveron presently has an average rating of “Hold” and a consensus target price of $5.50.

Longeveron Stock Up 0.1%

The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $0.89 and a 200-day moving average price of $0.72. The firm has a market cap of $24.02 million, a price-to-earnings ratio of -0.68 and a beta of -0.35.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.33 million. Longeveron had a negative return on equity of 202.41% and a negative net margin of 1,844.49%. On average, equities analysts forecast that Longeveron Inc. will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd bought a new stake in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.